BC Partners has begun the sale of Greek drugmaker Pharmathen, one of two healthcare divestments worth more than $3.6bn that the buyout firm wants to complete this year, with the hiring of investment bank Jefferies, two sources said.
Pharmathen focuses on developing, manufacturing and out-licensing complex generic drugs and could be valued at about $1.8bn, the sources told Reuters, speaking on condition of anonymity.
BC Partners is a British international investment firm with over $40bn of assets under management across private equity, credit and real estate in Europe and North America.
BC Partners declined to comment. Jefferies was not immediately available for comment.
Source: Reuters
Can’t stop reading? Read more
KKR powers past $723bn AUM on record fundraising and historic investment pace
KKR powers past $723bn AUM on record fundraising and historic investment pace KKR & Co. posted...
Ardian to acquire 90% stake in Centrotherm, boosting European semiconductor portfolio
Ardian to acquire 90% stake in Centrotherm, boosting European semiconductor portfolio Ardian has...
Beijing pushes fund managers to launch more equity funds in bid to revive markets
Beijing pushes fund managers to launch more equity funds in bid to revive markets Chinese...